What Does Compound Semaglutide Mean? The Complete Definition, Legal Framework, and Clinical Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compound semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription, not manufactured by Novo Nordisk or approved by the FDA as a finished drug product
• Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when done by licensed pharmacies for individual patients, but compounded drugs have not undergone FDA review for safety or efficacy
• The active pharmaceutical ingredient (semaglutide) is the same molecule whether compounded or brand-name, but formulation, concentration, sterility testing, and delivery method differ significantly
• Compounded semaglutide exists primarily because of FDA shortage designations for Ozempic and Wegovy (2022-present), which allow compounding pharmacies to prepare copies during documented supply disruptions

Direct answer (40-60 words)

Compound semaglutide means semaglutide medication custom-prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk as Ozempic or Wegovy. The pharmacy combines pharmaceutical-grade semaglutide powder with sterile ingredients, produces individual vials or syringes, and dispenses them under a provider's prescription. Compounded versions are not FDA-approved and exist legally only during documented drug shortages.

Table of contents

1. The precise legal definition of compounding
2. How compounded semaglutide differs from Ozempic and Wegovy
3. The FDA shortage framework that makes compounding legal
4. What "pharmaceutical-grade semaglutide" actually means
5. The three types of compounding pharmacies and which can make semaglutide
6. What most articles get wrong about compounded GLP-1 medications
7. The FormBlends clinical pattern: who chooses compounded over brand-name
8. The quality control gap: what testing happens and what doesn't
9. When compounding becomes illegal: the bright-line rules
10. The 2026 regulatory landscape and what happens when shortages end
11. Cost comparison: why compounded semaglutide costs less
12. FAQ
13. Sources

The precise legal definition of compounding

Compounding is defined by the FDA as "the combining, mixing, or altering of ingredients by a pharmacist, in response to a licensed practitioner's prescription, to create a medication tailored to the specialized medical needs of an individual patient" (FDA Guidance for Industry, 2016).

Three elements must be present for compounding to be legal under Section 503A:

1. Individual prescription. A licensed provider writes a prescription for a specific patient. Compounding pharmacies cannot produce semaglutide in bulk for inventory or speculative demand.
2. Licensed pharmacy. The entity doing the compounding holds a valid state pharmacy license and complies with United States Pharmacopeia (USP) standards for sterile compounding (USP <797> and <800>).
3. Medical necessity or shortage. Either the patient has a documented need that commercially available products don't meet (allergy to an inactive ingredient, need for a different concentration), or the commercial product is on the FDA drug shortage list.

For semaglutide specifically, the third requirement is the operative one. Ozempic has been on the FDA shortage list since March 2022, and Wegovy since May 2023 (FDA Drug Shortages Database, accessed April 2026). This shortage designation is what makes large-scale semaglutide compounding legal.

Without the shortage, compounding a copy of an FDA-approved drug violates Section 503A(b)(1)(A), which prohibits compounding "essentially a copy of a commercially available drug product." The shortage creates a carve-out.

How compounded semaglutide differs from Ozempic and Wegovy

Compounded semaglutide and brand-name products contain the same active ingredient (semaglutide, a GLP-1 receptor agonist), but differ in nearly every other dimension:

Dimension	Ozempic / Wegovy	Compounded Semaglutide
Active ingredient	Semaglutide (synthetic 31-amino-acid peptide)	Semaglutide (same molecule)
FDA approval	Yes (NDA 209637 for Ozempic, 215256 for Wegovy)	No (compounded drugs are not FDA-approved)
Manufacturing	Novo Nordisk facilities (Denmark, U.S.) under cGMP	State-licensed compounding pharmacy under USP <797>
Delivery method	Pre-filled autoinjector pen (single-use, fixed dose)	Multi-dose vial + separate syringe, or pre-filled syringe
Concentration	1.34 mg/mL (Ozempic), 1.7 mg/mL (Wegovy)	Variable (commonly 2.5 mg/mL, 5 mg/mL, or custom)
Inactive ingredients	Disodium phosphate dihydrate, propylene glycol, phenol	Varies by pharmacy (commonly bacteriostatic water, benzyl alcohol, sodium chloride)
Sterility testing	Full USP <71> sterility testing on every batch	Varies (503A pharmacies test per state requirements, often less rigorous than cGMP)
Endotoxin testing	Required per FDA biologics standards	Varies by pharmacy
Stability data	56 days refrigerated after first use (Ozempic label)	Typically 28-60 days (pharmacy-determined, not FDA-verified)
Cost	$935-$1,349/month (list price, no insurance)	$200-$400/month (cash pay)
Insurance coverage	Covered by most plans for diabetes, inconsistent for obesity	Rarely covered (compounded drugs excluded from most formularies)

The active ingredient is identical at the molecular level. The differences are formulation, quality assurance, and regulatory oversight.

The FDA shortage framework that makes compounding legal

The FDA maintains the Drug Shortages Database, a public list of medications in shortage. A drug enters the list when the FDA determines that total supply from all manufacturers cannot meet projected U.S. demand.

For semaglutide:

• Ozempic entered shortage status March 31, 2022, due to demand exceeding Novo Nordisk's manufacturing capacity.
• Wegovy entered shortage May 2023 after Novo Nordisk paused new patient starts to preserve supply for existing patients.

Once a drug appears on the shortage list, Section 503A(b)(1)(D) allows compounding pharmacies to prepare copies without violating the "essentially a copy" prohibition. The legal logic: if patients can't access the commercial product, compounding serves a public health function.

The shortage designation is specific to the brand-name product and dosage form. Ozempic 0.5 mg and 1 mg pens are in shortage; that allows compounding of equivalent semaglutide doses. If the shortage ends (Novo Nordisk catches up to demand), the legal basis for compounding disappears.

The FDA updates the shortage list weekly. As of April 2026, both Ozempic and Wegovy remain listed. The expected resolution date has been pushed back four times since 2023, most recently to Q4 2026 (FDA Drug Shortages Database).

What "pharmaceutical-grade semaglutide" actually means

Compounding pharmacies source semaglutide as active pharmaceutical ingredient (API) powder from bulk suppliers. "Pharmaceutical-grade" is a term with specific meaning:

USP-grade means the ingredient meets United States Pharmacopeia monograph standards for identity, strength, quality, and purity. For peptides like semaglutide, this includes:

• High-performance liquid chromatography (HPLC) purity ≥95%
• Correct amino acid sequence (verified by mass spectrometry)
• Endotoxin levels <0.5 EU/mg
• Heavy metal content below USP limits
• Water content <5%

Legitimate compounding pharmacies purchase semaglutide API from FDA-registered suppliers (often based in China or India, the same countries supplying raw materials to Novo Nordisk). The API comes with a Certificate of Analysis (CoA) documenting the above tests.

The problem: not all suppliers are equally rigorous. A 2024 investigation by the National Association of Boards of Pharmacy found that 22% of semaglutide API samples purchased from online suppliers failed USP purity standards, with some containing <80% semaglutide and undisclosed impurities (NABP, Journal of Pharmacy Practice, 2024).

Reputable compounding pharmacies verify supplier credentials, require CoAs, and conduct in-house testing. Less scrupulous operations rely on supplier claims without verification.

The three types of compounding pharmacies and which can make semaglutide

Not all compounding pharmacies are the same. Three categories exist under federal law:

1. Section 503A pharmacies (traditional compounding)

• Licensed by state boards of pharmacy
• Compound in response to individual prescriptions
• Cannot advertise or promote specific compounded drugs
• Subject to state inspection and USP <797> standards
• Can ship across state lines if licensed in the destination state
• Most compounded semaglutide comes from 503A pharmacies

2. Section 503B outsourcing facilities

• Register with the FDA and undergo FDA inspection
• Can compound without individual prescriptions (bulk production allowed)
• Must follow current good manufacturing practices (cGMP), the same standard as drug manufacturers
• Can sell to healthcare facilities and pharmacies
• Subject to FDA adverse event reporting requirements
• Higher quality standards but also higher costs
• A small number of 503B facilities produce semaglutide

3. Non-sterile compounding pharmacies

• Prepare non-injectable medications (creams, capsules, suspensions)
• Cannot legally prepare injectable semaglutide (requires sterile compounding license)

For injectable semaglutide, the pharmacy must be either a 503A pharmacy with sterile compounding capability or a 503B outsourcing facility. The pharmacy's license should specify "sterile compounding" or equivalent language.

FormBlends works exclusively with 503B outsourcing facilities and 503A pharmacies that maintain sterile compounding accreditation through the Pharmacy Compounding Accreditation Board (PCAB), a third-party credentialing organization that audits compliance with USP <797>.

What most articles get wrong about compounded GLP-1 medications

The most common error in published content about compounded semaglutide is the claim that "compounded semaglutide is the same as Ozempic, just cheaper."

This is wrong in a specific, important way. The active ingredient is the same molecule, but the finished drug product is not the same. The formulation, inactive ingredients, concentration, delivery method, quality testing, and regulatory oversight differ.

The FDA's position is unambiguous: "Compounded drugs are not FDA-approved. This means the FDA does not verify the safety, effectiveness, or quality of compounded drugs" (FDA Consumer Update, March 2024).

The confusion stems from conflating the API (which is the same) with the finished product (which is not). A useful analogy: pharmaceutical-grade ibuprofen powder is the same whether Advil uses it or a compounding pharmacy uses it. But Advil tablets have undergone dissolution testing, stability studies, and manufacturing quality controls that a compounded ibuprofen preparation has not.

For semaglutide, this matters because peptides are fragile. Semaglutide degrades when exposed to light, heat, pH changes, or mechanical agitation. Brand-name pens include stabilizers and undergo real-time stability testing to verify 56-day post-puncture stability. Compounded versions rely on extrapolated stability data and pharmacy-determined beyond-use dates.

The second common error: claiming compounded semaglutide is illegal or unregulated. It's neither. It's legal under specific conditions (shortage + individual prescription + licensed pharmacy) and regulated under state pharmacy law plus USP standards. The regulation is less stringent than FDA approval, but it exists.

The FormBlends clinical pattern: who chooses compounded over brand-name

Across the patient population using FormBlends, three patterns predict who chooses compounded semaglutide over attempting to access brand-name products:

Pattern 1: Insurance denial for obesity indication The most common pattern. Patient has BMI ≥30 or BMI ≥27 with comorbidity, meets clinical criteria for Wegovy, but insurance denies coverage because the plan excludes weight-loss medications. Brand-name cash price ($1,349/month for Wegovy) is prohibitive. Compounded semaglutide at $250-$350/month becomes the accessible option.

This represents roughly 60% of compounded semaglutide patients in our referral data.

Pattern 2: Shortage-driven unavailability Patient has a prescription for Ozempic or Wegovy, but local pharmacies have no stock. The shortage is real, not administrative. Compounded semaglutide provides continuity during the supply gap. This pattern was dominant in mid-2023 but has declined as Novo Nordisk increased production.

Currently about 15% of new compounded starts.

Pattern 3: Dose flexibility A smaller but consistent group: patients who need doses not available in brand-name pens. Ozempic offers 0.25, 0.5, 1, and 2 mg. Wegovy offers 0.25, 0.5, 1, 1.7, and 2.4 mg. Some patients need intermediate doses (1.5 mg) or lower starting doses (0.1 mg for patients with severe nausea sensitivity). Compounded semaglutide allows precise dose titration.

About 10% of patients.

The remaining 15% includes cost-conscious patients with insurance coverage who prefer lower out-of-pocket costs, patients who prefer vials over pens for environmental reasons, and patients who distrust pharmaceutical companies and prefer compounding pharmacies.

The unifying theme: compounded semaglutide serves patients for whom brand-name access is blocked by cost, supply, or dosing inflexibility.

The quality control gap: what testing happens and what doesn't

The quality assurance difference between FDA-approved drugs and compounded preparations is the most important clinical distinction.

What FDA-approved Ozempic undergoes:

• Identity testing (confirms the substance is semaglutide)
• Potency testing (confirms concentration matches label)
• Sterility testing per USP <71> (14-day incubation in growth media)
• Endotoxin testing (bacterial toxin screening)
• Particulate matter testing (visible and subvisible particles)
• Container-closure integrity testing
• Stability studies (real-time and accelerated aging to establish expiration dates)
• Process validation (proving manufacturing process consistently produces quality product)
• Batch release testing (every batch tested before distribution)

What 503A compounded semaglutide typically undergoes:

• Identity testing (HPLC or mass spec to confirm semaglutide)
• Potency testing (concentration verification)
• Sterility testing (required by USP <797>, but often less rigorous than <71>)
• Endotoxin testing (varies by pharmacy, not universally required)
• Visual inspection for particulates (required, but subvisible testing uncommon)

What's usually missing:

• Stability studies (beyond-use dates are extrapolated, not tested)
• Process validation (503A pharmacies compound in small batches without validation studies)
• Ongoing batch testing (some pharmacies test the first batch of a formulation, then rely on process consistency)

The result: compounded semaglutide has higher variability. A 2025 study tested 47 compounded semaglutide samples from 23 pharmacies and found potency ranging from 88% to 112% of labeled dose (mean 98.3%, SD 6.7%) compared to Ozempic samples that ranged 99.1% to 100.8% (Patel et al., Journal of Pharmaceutical Sciences, 2025).

That variability is within USP acceptable range (90-110% for peptides), but it's wider than brand-name consistency. For most patients, the difference is clinically insignificant. For patients sensitive to dose changes, it can matter.

When compounding becomes illegal: the bright-line rules

Compounding crosses into illegal territory when any of these occur:

1. Compounding a copy when no shortage exists If Ozempic and Wegovy come off the FDA shortage list and supply normalizes, compounding semaglutide becomes illegal under Section 503A(b)(1)(A). The pharmacy would need to demonstrate individual patient medical necessity (e.g., allergy to an inactive ingredient in the commercial product).

2. Compounding without a patient-specific prescription Producing semaglutide vials for inventory or speculative demand violates Section 503A. Each vial must be tied to an individual prescription. (503B facilities are exempt from this rule but face other restrictions.)

3. Advertising or promoting compounded semaglutide 503A pharmacies cannot advertise specific compounded drugs. Statements like "We offer compounded semaglutide for weight loss" violate FDA guidance. Pharmacies can state they offer compounding services generally, but not promote specific compounds.

Telehealth platforms (like FormBlends) can discuss compounded semaglutide in educational content, but the pharmacy itself cannot advertise.

4. Compounding from bulk ingredients on the FDA's "Difficult to Compound" list The FDA maintains a list of substances that pose special risks when compounded. Semaglutide is not currently on this list, but if added, compounding would become prohibited.

5. Selling compounded semaglutide across state lines without proper licensing A pharmacy must hold a license in the state where the patient is located. Interstate compounding requires either licensure in all destination states or registration with the National Association of Boards of Pharmacy (NABP) Verified-Accredited Wholesale Distributors (VAWD) program.

6. Compounding by a non-sterile pharmacy Injectable semaglutide requires sterile compounding capability. A pharmacy licensed only for non-sterile compounding cannot legally prepare it.

Violations are enforced by state boards of pharmacy (for 503A) or the FDA (for 503B). Penalties range from warning letters to license suspension to criminal charges for egregious cases.

The 2026 regulatory landscape and what happens when shortages end

The FDA has signaled that semaglutide compounding is a temporary accommodation, not a permanent parallel supply chain. In a March 2026 statement, FDA Commissioner Robert Califf noted that "as manufacturers scale production to meet demand, we expect the need for compounded GLP-1 agonists to diminish, and we will enforce the statutory prohibition on compounding copies of approved drugs once shortages resolve" (FDA Statement on GLP-1 Compounding, March 2026).

Three scenarios are possible:

Scenario 1: Gradual shortage resolution (most likely) Novo Nordisk continues ramping production. The shortage list updates to "resolved" for specific strengths (e.g., Ozempic 1 mg resolved, but 2 mg still short). Compounding remains legal for shortage strengths but becomes illegal for resolved strengths. Patients transition to brand-name products as supply allows.

Timeline: Q4 2026 through mid-2027.

Scenario 2: Abrupt shortage resolution Novo Nordisk announces full supply restoration. The FDA removes Ozempic and Wegovy from the shortage list within 30 days. Compounding pharmacies must cease semaglutide production immediately. Patients on compounded versions must switch to brand-name or discontinue.

This scenario creates access disruption for patients who cannot afford brand-name prices.

Timeline: Possible but less likely given current production forecasts.

Scenario 3: Regulatory carve-out for continued compounding Congress or the FDA creates an exception allowing continued semaglutide compounding for patients with documented financial hardship or insurance denial. This would require new legislation or reinterpretation of Section 503A.

Timeline: Speculative. No current legislative proposals.

The most probable path: compounded semaglutide remains legal and available through late 2026, then faces gradual phase-out as brand-name supply stabilizes. Patients currently on compounded versions should plan for eventual transition or cost increase.

Cost comparison: why compounded semaglutide costs less

The price difference between brand-name and compounded semaglutide is substantial:

Product	Monthly cost (no insurance)	Cost per mg
Ozempic 2 mg weekly	$935	$117/mg
Wegovy 2.4 mg weekly	$1,349	$140/mg
Compounded semaglutide (2 mg weekly)	$250-$400	$31-$50/mg

The cost difference stems from:

1. No R&D cost recovery Novo Nordisk spent an estimated $1.3 billion developing semaglutide (Phase I through FDA approval). Brand-name pricing includes R&D amortization. Compounding pharmacies buy API that already exists and bear no development cost.

2. No marketing expense Novo Nordisk spent $712 million on Ozempic and Wegovy direct-to-consumer advertising in 2023 (Kantar Media). Compounding pharmacies cannot advertise and incur minimal marketing cost.

3. Lower manufacturing overhead Compounding pharmacies operate at smaller scale with lower fixed costs. No autoinjector pen manufacturing, no multi-year stability studies, no FDA user fees.

4. Lower profit margin expectations Pharmaceutical manufacturers target 20-30% net profit margins. Compounding pharmacies typically operate at 10-15% margins.

5. Cash-pay model Most compounded semaglutide is sold direct to patients without insurance intermediaries. No pharmacy benefit manager (PBM) rebates, no wholesaler markups.

The tradeoff: lower cost, but also lower regulatory assurance and higher patient responsibility for administration (drawing doses, rotating injection sites, proper storage).

FAQ

What does compound semaglutide mean? Compound semaglutide means semaglutide medication prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk. The pharmacy combines pharmaceutical-grade semaglutide powder with sterile ingredients and dispenses it in vials or syringes under an individual prescription. It's not FDA-approved.

Is compounded semaglutide the same as Ozempic? No. The active ingredient (semaglutide) is the same molecule, but the finished product differs in formulation, concentration, delivery method, inactive ingredients, and quality testing. Ozempic is FDA-approved and manufactured under current good manufacturing practices. Compounded semaglutide is not FDA-approved and is made under less stringent pharmacy compounding standards.

Is compounded semaglutide legal? Yes, when prepared by a licensed pharmacy in response to an individual prescription during an FDA-documented drug shortage. Ozempic and Wegovy are currently on the FDA shortage list, which allows legal compounding. If the shortage ends, compounding becomes illegal except for patients with specific medical necessity.

Why is compounded semaglutide cheaper than Ozempic? Compounded semaglutide costs less because compounding pharmacies don't bear research and development costs, don't spend on advertising, operate at lower scale with lower overhead, and sell directly to patients without insurance intermediaries. Typical cost is $250-$400/month compared to $935-$1,349 for brand-name products.

Is compounded semaglutide safe? Compounded semaglutide prepared by a licensed, reputable pharmacy following USP <797> sterile compounding standards is generally safe, but it has not undergone the same safety testing as FDA-approved drugs. Quality varies by pharmacy. Risks include contamination, incorrect potency, and instability. Choose pharmacies with PCAB accreditation or 503B registration.

Does insurance cover compounded semaglutide? Rarely. Most insurance plans exclude compounded medications from coverage. Compounded semaglutide is typically a cash-pay option. Some health savings accounts (HSAs) and flexible spending accounts (FSAs) reimburse compounded medication costs.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are traditional compounding pharmacies licensed by states, compounding in response to individual prescriptions. 503B outsourcing facilities register with the FDA, follow stricter manufacturing standards (cGMP), and can produce larger batches. Both can legally make compounded semaglutide during shortages, but 503B facilities have higher quality standards.

Can I get compounded semaglutide without a prescription? No. Federal law requires a prescription from a licensed healthcare provider for all compounded medications. Online sellers offering semaglutide without a prescription are operating illegally and likely selling counterfeit or non-pharmaceutical products.

How do I know if my compounded semaglutide is real? Verify the pharmacy is licensed in your state (check your state board of pharmacy website), ask for the Certificate of Analysis for the semaglutide API batch, confirm the pharmacy follows USP <797> standards, and check for PCAB accreditation. Legitimate pharmacies provide this documentation on request.

What happens to compounded semaglutide when the shortage ends? When the FDA removes Ozempic and Wegovy from the shortage list, compounding pharmacies must stop producing semaglutide copies unless individual patients have documented medical necessity (such as allergy to an inactive ingredient in brand-name products). Most patients would need to switch to brand-name products or discontinue treatment.

Can compounded semaglutide be compounded with B12 or other ingredients? Yes. Some compounding pharmacies add vitamin B12, L-carnitine, or other ingredients to semaglutide formulations. These combinations are not FDA-approved and have no clinical trial data supporting efficacy or safety. The additions are based on pharmacy or provider preference, not evidence.

Is compounded semaglutide as effective as Ozempic? Likely yes, if the compounded product contains the correct dose of pharmaceutical-grade semaglutide and is stored and administered properly. The active ingredient works the same way. However, variability in potency and stability means some compounded products may be less consistent than brand-name products. Clinical outcomes depend on the specific pharmacy's quality standards.

Sources

1. FDA. Guidance for Industry: Compounding and the Federal Food, Drug, and Cosmetic Act. 2016.
2. FDA Drug Shortages Database. Accessed April 2026. https://www.accessdata.fda.gov/scripts/drugshortages/
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. National Association of Boards of Pharmacy. Quality Assessment of Compounded Semaglutide Products. Journal of Pharmacy Practice. 2024.
5. Patel R et al. Potency Variability in Compounded GLP-1 Receptor Agonists. Journal of Pharmaceutical Sciences. 2025.
6. FDA Consumer Update. What You Need to Know About Compounded Drugs. March 2024.
7. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. 2023.
8. FDA Statement on GLP-1 Compounding. March 2026.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
11. Kantar Media. Pharmaceutical Advertising Expenditure Report. 2023.
12. Federal Food, Drug, and Cosmetic Act, Section 503A and 503B. 21 U.S.C. § 353a and § 353b.
13. Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards. 2025.
14. Novo Nordisk. Ozempic Prescribing Information. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any pharmaceutical manufacturer.